Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Verhoef

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Acta Haematologica|June 5, 2019
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in BelgiumTimothy Devos, Gregor Verhoef, Eva Steel, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
The New England Journal of Medicine|March 5, 2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphomaTadeusz Robak, Huiqiang Huang, Jie Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Haematologica|January 21, 2018
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Acta Haematologica|June 5, 2019
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in BelgiumTimothy Devos, Gregor Verhoef, Eva Steel, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
The New England Journal of Medicine|March 5, 2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphomaTadeusz Robak, Huiqiang Huang, Jie Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Haematologica|January 21, 2018
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Pageof 10